• Pegaspargase, sold under the brand name Oncaspar, is a medication used in the treatment of acute lymphoblastic leukemia (ALL). (wikipedia.org)
  • Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL). (hsa.gov.sg)
  • 1 month, also take Oncaspar and have Acute lymphocytic leukemia (all). (ehealthme.com)
  • Oncaspar ® is used in the treatment of acute lymphocytic leukaemia, a disease affecting especially children. (xbrane.com)
  • The Dublin-based company said the deal covers its already-marketed drug Oncaspar (pergaspargase) for acute lymphoblastic leukaemia (ALL), as well as ex-US rights to pancreatic cancer therapy Onivyde (irinotecan pegylated liposomal formulation) and long-acting Oncaspar follow-up calaspargase pegol - under FDA review for ALL. (pharmemed.com)
  • The existing regimes and drugs market currently includes three regimens (Hyper-CVAD, Linker, and CALGB 8811) and three monotherapy drugs (Oncaspar, Clolar, and Arranon). (powershow.com)
  • Global Oncaspar Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. (bharatbook.com)
  • The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028.This research study of Oncaspar involved the extensive usage of both primary and secondary data sources. (bharatbook.com)
  • Oncaspar (pegaspargase) is a pegylated version of L-asparaginase, which converts L-asparagine to ammonia and L-aspartic acid, reducing available asparagine resulting in decreased protein synthesis, inhibition of tumor cell proliferation, and increased apoptosis (NCI Drug Dictionary). (jax.org)
  • Baxalta's early oncology presence rests on three licensed in projects: CTI Biopharma's not particularly promising Jak inhibitor pacritinib, Sigma-Tau's marketed pegaspargase formulation Oncaspar, and Merrimack's nanoformulation of irinotecan MM-398, recently filed for pancreatic cancer. (evaluate.com)
  • Xbrane is accelerating the development of Xcimzane (certoizumab pegol (Cimzia ® ) biosimilar), and Xoncane (pegaspargase (Oncaspar ® ) biosimilar. (xbrane.com)
  • Estudio de estabilidad fisiciquimica y microbiologica de jeringas de morfina 2 mG/mL en suero fisiologico para administracion en bomba de infusion. (stabilis.org)
  • The Oncaspar Market Research report incorporate value chain analysis for each of the product type. (bharatbook.com)
  • Value chain analysis offers in depth information about value addition at each stage.The study includes drivers and restraints for Oncaspar Market along with their impact on demand during the forecast period. (bharatbook.com)
  • Our study Oncaspar Market helps user to make precise decision in order to expand their market presence and increase market share. (bharatbook.com)
  • The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Oncaspar market in 2020. (bharatbook.com)
  • Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Oncaspar market study focused on including all the primary level, secondary level and tertiary level competitors in the report. (bharatbook.com)
  • The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Oncaspar market. (bharatbook.com)
  • 4. The report starts with Oncaspar market statistics and moves to important points, with dependent markets categorized by market trend by application. (bharatbook.com)
  • The FDA approved in November an intravenous route of administration for pegaspargase injection (Oncaspar, made by Enzon Pharmaceuticals, Inc.). The pediatric product was previously approved for delivery via intramuscular injection, which is often painful to patients. (medscape.com)
  • Pegaspargase, sold under the brand name Oncaspar, is a medication used in the treatment of acute lymphoblastic leukemia (ALL). (wikipedia.org)
  • these happened during treatment with asparaginase (Elspar) or pegaspargase (Oncaspar). (nih.gov)
  • Pegylated formulations of E. coli-derived asparaginase (pegaspargase) became available and were approved for use in 1994 and are currently available under the brand name Oncaspar. (nih.gov)
  • 9. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). (nih.gov)
  • Oncaspar (pegaspargase) is a pegylated version of L-asparaginase, which converts L-asparagine to ammonia and L-aspartic acid, reducing available asparagine resulting in decreased protein synthesis, inhibition of tumor cell proliferation, and increased apoptosis (NCI Drug Dictionary). (jax.org)
  • Recently, Servier shared some information about access of ASPARLAS® (calaspargase pegol-mknl) and ONCASPAR® (pegaspargase), and wanted to ensure providers are aware of the changes Servier is making in the coming months. (sumocancer.org)
  • Discontinue ONCASPAR in patients with serious hypersensitivity reactions. (nih.gov)
  • Discontinue ONCASPAR in patients with serious thrombotic events. (nih.gov)
  • Discontinue ONCASPAR in patients with pancreatitis. (nih.gov)
  • The recommended dose of ONCASPAR for patients up to and including 21 years of age is 2,500 International Units/m 2 intramuscularly or intravenously no more frequently than every 14 days. (nih.gov)
  • ONCASPAR will continue to be available for patients aged 22 years and older, managed through a new HUB. (sumocancer.org)
  • Do not administer ONCASPAR if drug has been frozen, stored at room temperature for more than 48 hours, or shaken or vigorously agitated. (nih.gov)
  • The Company has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). Enzon's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform and the Locked Nucleic Acid (LNA) technology. (science20.com)
  • Meanwhile, Servier will land an "immediate presence" in the U.S. with products such as Oncaspar, which Shire nabbed in its Baxalta buyout. (crazzfiles.com)